Stem definition | Drug id | CAS RN |
---|---|---|
steroids, progestogens | 1667 | 595-33-5 |
Dose | Unit | Route |
---|---|---|
5 | mg | O |
0.16 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 60 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 23.22 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 90 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 18, 1971 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Death | 102.08 | 20.21 | 142 | 4868 | 325237 | 50274877 |
Decreased appetite | 85.31 | 20.21 | 102 | 4908 | 200821 | 50399293 |
Neutropenia | 64.15 | 20.21 | 76 | 4934 | 147889 | 50452225 |
Malignant neoplasm progression | 61.16 | 20.21 | 52 | 4958 | 68072 | 50532042 |
Disease progression | 53.11 | 20.21 | 56 | 4954 | 95810 | 50504304 |
Metastases to liver | 50.75 | 20.21 | 29 | 4981 | 20075 | 50580039 |
Deep vein thrombosis | 48.22 | 20.21 | 47 | 4963 | 73257 | 50526857 |
Dehydration | 46.73 | 20.21 | 66 | 4944 | 152383 | 50447731 |
Asthenia | 40.49 | 20.21 | 94 | 4916 | 318948 | 50281166 |
Metastases to bone | 37.66 | 20.21 | 23 | 4987 | 17972 | 50582142 |
Diarrhoea | 30.71 | 20.21 | 127 | 4883 | 588349 | 50011765 |
Oestrogen receptor assay positive | 28.56 | 20.21 | 7 | 5003 | 436 | 50599678 |
Papillary thyroid cancer | 25.49 | 20.21 | 9 | 5001 | 2006 | 50598108 |
Meningioma | 24.12 | 20.21 | 10 | 5000 | 3439 | 50596675 |
Breast cancer | 23.61 | 20.21 | 25 | 4985 | 42865 | 50557249 |
Thoracic vertebral fracture | 22.52 | 20.21 | 10 | 5000 | 4063 | 50596051 |
Weight decreased | 21.50 | 20.21 | 59 | 4951 | 221186 | 50378928 |
Plasma cell myeloma | 20.41 | 20.21 | 20 | 4990 | 31302 | 50568812 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malignant neoplasm progression | 77.24 | 19.50 | 84 | 5826 | 73775 | 29494842 |
Death | 69.73 | 19.50 | 186 | 5724 | 341898 | 29226719 |
Dehydration | 63.41 | 19.50 | 95 | 5815 | 114653 | 29453964 |
Asthenia | 63.14 | 19.50 | 135 | 5775 | 215115 | 29353502 |
Decreased appetite | 60.78 | 19.50 | 106 | 5804 | 145236 | 29423381 |
Adrenal insufficiency | 50.38 | 19.50 | 30 | 5880 | 11084 | 29557533 |
Pneumonia | 49.57 | 19.50 | 158 | 5752 | 320014 | 29248603 |
Fatigue | 46.01 | 19.50 | 153 | 5757 | 316668 | 29251949 |
Disease progression | 41.20 | 19.50 | 65 | 5845 | 81851 | 29486766 |
Plasma cell myeloma | 31.58 | 19.50 | 38 | 5872 | 37077 | 29531540 |
Diarrhoea | 30.45 | 19.50 | 139 | 5771 | 332559 | 29236058 |
Anaemia | 24.65 | 19.50 | 92 | 5818 | 200859 | 29367758 |
Dysphagia | 24.09 | 19.50 | 41 | 5869 | 54885 | 29513732 |
Weight decreased | 20.97 | 19.50 | 72 | 5838 | 150833 | 29417784 |
Pulmonary embolism | 20.03 | 19.50 | 46 | 5864 | 76488 | 29492129 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Death | 109.47 | 18.35 | 207 | 7877 | 482498 | 64008150 |
Dehydration | 96.64 | 18.35 | 127 | 7957 | 216636 | 64274012 |
Decreased appetite | 96.05 | 18.35 | 145 | 7939 | 281144 | 64209504 |
Asthenia | 69.19 | 18.35 | 160 | 7924 | 427884 | 64062764 |
Adrenal insufficiency | 69.01 | 18.35 | 40 | 8044 | 22447 | 64468201 |
Malignant neoplasm progression | 64.48 | 18.35 | 75 | 8009 | 112796 | 64377852 |
Pneumonia | 56.77 | 18.35 | 176 | 7908 | 559400 | 63931248 |
Disease progression | 52.47 | 18.35 | 76 | 8008 | 141604 | 64349044 |
Plasma cell myeloma | 51.22 | 18.35 | 44 | 8040 | 46031 | 64444617 |
Diarrhoea | 39.72 | 18.35 | 187 | 7897 | 722517 | 63768131 |
Pulmonary embolism | 35.71 | 18.35 | 65 | 8019 | 146291 | 64344357 |
Anaemia | 34.52 | 18.35 | 115 | 7969 | 378565 | 64112083 |
Fatigue | 33.56 | 18.35 | 183 | 7901 | 748547 | 63742101 |
Neutropenia | 31.58 | 18.35 | 83 | 8001 | 239541 | 64251107 |
Deep vein thrombosis | 31.27 | 18.35 | 51 | 8033 | 105131 | 64385517 |
Drug ineffective | 29.90 | 18.35 | 37 | 8047 | 840210 | 63650438 |
Androgen deficiency | 24.62 | 18.35 | 5 | 8079 | 102 | 64490546 |
Pleural effusion | 24.50 | 18.35 | 51 | 8033 | 126508 | 64364140 |
Mental status changes | 24.36 | 18.35 | 34 | 8050 | 61128 | 64429520 |
Constipation | 23.90 | 18.35 | 73 | 8011 | 229264 | 64261384 |
Failure to thrive | 22.96 | 18.35 | 15 | 8069 | 10389 | 64480259 |
Blood testosterone decreased | 22.95 | 18.35 | 9 | 8075 | 2116 | 64488532 |
Meningioma | 20.72 | 18.35 | 10 | 8074 | 3872 | 64486776 |
Cachexia | 19.63 | 18.35 | 13 | 8071 | 9204 | 64481444 |
Secondary adrenocortical insufficiency | 18.73 | 18.35 | 8 | 8076 | 2337 | 64488311 |
Malnutrition | 18.71 | 18.35 | 17 | 8067 | 19108 | 64471540 |
None
Source | Code | Description |
---|---|---|
ATC | G03AA04 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
ATC | G03AB01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, sequential preparations |
ATC | G03AC05 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens |
ATC | G03DB02 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS Pregnadien derivatives |
ATC | G03FA08 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS AND ESTROGENS IN COMBINATION Progestogens and estrogens, fixed combinations |
ATC | G03FB04 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS AND ESTROGENS IN COMBINATION Progestogens and estrogens, sequential preparations |
ATC | L02AB01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONES AND RELATED AGENTS Progestogens |
FDA CS | M0447349 | Progesterone Congeners |
FDA EPC | N0000175602 | Progestin |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D018931 | Antineoplastic Agents, Hormonal |
MeSH PA | D003270 | Contraceptive Agents |
MeSH PA | D003271 | Contraceptive Agents, Female |
MeSH PA | D000080066 | Contraceptive Agents, Hormonal |
MeSH PA | D003278 | Contraceptives, Oral, Hormonal |
MeSH PA | D003280 | Contraceptives, Oral, Synthetic |
MeSH PA | D012102 | Reproductive Control Agents |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:49323 | contraceptive drugs |
CHEBI has role | CHEBI:49326 | synthetic oral contraceptives |
CHEBI has role | CHEBI:50779 | appetite enhancing drug |
CHEBI has role | CHEBI:59826 | progestins |
MeSH PA | D019167 | Appetite Stimulants |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D000697 | Central Nervous System Stimulants |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Endometrial carcinoma | indication | 254878006 | DOID:2871 |
Hormone receptor positive malignant neoplasm of breast | indication | 417181009 | |
Nutritional deficiency associated with AIDS | indication | 420691000 | |
Cachexia due to HIV | indication | ||
Anorexia from HIV | indication | ||
Malignant tumor of ovary | off-label use | 363443007 | DOID:2394 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Chronic heart failure | contraindication | 48447003 | |
Male hypogonadism | contraindication | 48723006 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pregnancy, function | contraindication | 289908002 | |
Thromboembolic disorder | contraindication | 371039008 | |
Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
Species | Use | Relation |
---|---|---|
Dogs | Alleviation of false pregnancy | Indication |
Dogs | Postponement of estrus | Indication |
Product | Applicant | Ingredients |
---|---|---|
Ovaban Tablets 20 mg, Ovaban Tablets 5 mg | Intervet Inc. | 1 |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
125MG/ML | MEGACE ES | ENDO PHARMS INC | N021778 | July 5, 2005 | RX | SUSPENSION | ORAL | 7101576 | April 22, 2024 | TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) |
125MG/ML | MEGACE ES | ENDO PHARMS INC | N021778 | July 5, 2005 | RX | SUSPENSION | ORAL | 9040088 | April 22, 2024 | TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) |
125MG/ML | MEGACE ES | ENDO PHARMS INC | N021778 | July 5, 2005 | RX | SUSPENSION | ORAL | 9101540 | April 22, 2024 | TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) |
125MG/ML | MEGACE ES | ENDO PHARMS INC | N021778 | July 5, 2005 | RX | SUSPENSION | ORAL | 9101549 | April 22, 2024 | TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) |
125MG/ML | MEGACE ES | ENDO PHARMS INC | N021778 | July 5, 2005 | RX | SUSPENSION | ORAL | 9107827 | April 22, 2024 | TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Progesterone receptor | Nuclear hormone receptor | AGONIST | DRUGBANK | CHEMBL | |||||
Multidrug resistance protein 1 | Transporter | WOMBAT-PK | |||||||
Glucocorticoid receptor | Nuclear hormone receptor | Ki | 8.06 | DRUG MATRIX | |||||
Cytochrome P450 2C9 | Enzyme | IC50 | 5 | DRUG MATRIX | |||||
Androgen receptor | Transcription factor | Ki | 7.70 | DRUG MATRIX | |||||
Progesterone receptor | Transcription factor | Ki | 8.84 | DRUG MATRIX |
ID | Source |
---|---|
4022205 | VUID |
N0000020211 | NUI |
D00952 | KEGG_DRUG |
4018133 | VANDF |
4022205 | VANDF |
C0065879 | UMLSCUI |
CHEBI:6723 | CHEBI |
CHEBI:6722 | CHEBI |
CHEMBL1201139 | ChEMBL_ID |
DB00351 | DRUGBANK_ID |
D019290 | MESH_DESCRIPTOR_UI |
11683 | PUBCHEM_CID |
9128 | IUPHAR_LIGAND_ID |
3562-63-8 | SECONDARY_CAS_RN |
TJ2M0FR8ES | UNII |
19090 | PUBCHEM_CID |
29451 | RXNORM |
1784 | MMSL |
5036 | MMSL |
d01348 | MMSL |
002667 | NDDF |
004823 | NDDF |
126091007 | SNOMEDCT_US |
126092000 | SNOMEDCT_US |
38578004 | SNOMEDCT_US |
C0025175 | UMLSCUI |
1529 | INN_ID |
D008535 | MESH_DESCRIPTOR_UI |
EA6LD1M70M | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0887 | SUSPENSION | 625 mg | ORAL | ANDA | 30 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0945 | SUSPENSION | 400 mg | ORAL | ANDA | 21 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-4776 | SUSPENSION | 40 mg | ORAL | ANDA | 24 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0606 | TABLET | 20 mg | ORAL | ANDA | 20 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0607 | TABLET | 40 mg | ORAL | ANDA | 20 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-3571 | TABLET | 40 mg | ORAL | ANDA | 19 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7072 | SUSPENSION | 40 mg | ORAL | ANDA | 22 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7236 | TABLET | 40 mg | ORAL | ANDA | 17 sections |
Megace ES | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-254 | SUSPENSION | 125 mg | ORAL | NDA | 11 sections |
MEGESTOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-898 | SUSPENSION | 40 mg | ORAL | ANDA | 4 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0060 | SUSPENSION | 40 mg | ORAL | ANDA | 12 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0907 | SUSPENSION | 40 mg | ORAL | ANDA | 20 sections |
Megace ES | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0949 | SUSPENSION | 125 mg | ORAL | NDA | 25 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-041 | SUSPENSION | 125 mg | ORAL | ANDA | 27 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33358-903 | SUSPENSION | 40 mg | ORAL | ANDA | 10 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-230 | SUSPENSION | 125 mg | ORAL | NDA AUTHORIZED GENERIC | 26 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-230 | SUSPENSION | 125 mg | ORAL | NDA AUTHORIZED GENERIC | 26 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-289 | TABLET | 20 mg | ORAL | ANDA | 19 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-289 | TABLET | 20 mg | ORAL | ANDA | 19 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-290 | TABLET | 40 mg | ORAL | ANDA | 19 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-290 | TABLET | 40 mg | ORAL | ANDA | 19 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-907 | SUSPENSION | 40 mg | ORAL | ANDA | 22 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-907 | SUSPENSION | 40 mg | ORAL | ANDA | 22 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-859 | SUSPENSION | 40 mg | ORAL | ANDA | 19 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-859 | SUSPENSION | 40 mg | ORAL | ANDA | 19 sections |
Megestrol acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51991-313 | SUSPENSION | 125 mg | ORAL | ANDA | 28 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0614 | TABLET | 40 mg | ORAL | ANDA | 18 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-1629 | TABLET | 40 mg | ORAL | ANDA | 19 sections |
MEGESTROL ACETATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5389 | SUSPENSION | 40 mg | ORAL | ANDA | 24 sections |
MEGACE ES | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5572 | SUSPENSION | 125 mg | ORAL | NDA | 27 sections |